GYRE THERAPEUTICS, INC. (GYRE) Form S-3 — Jun 22, 2026
Gyre Therapeutics filed a shelf registration statement on Form S-3 to allow selling stockholders to resell up to 30,221,531 shares of common stock. These shares consist of 11,735,356 common shares and 18,486,175 shares issuable upon the conversion of 3,697,235 shares of Series B Preferred Stock issued in connection with the company's merger with Cullgen Inc. The filing fulfills obligations under a Registration Rights Agreement entered into at the closing of the merger, which valued Cullgen at approximately $300 million. Gyre will not receive any proceeds from the resale of these shares, which are being offered by former Cullgen stockholders and other affiliated entities.
Key figures
- Shares Offered
- 30,221,531
- Merger value
- 300,000,000
- Last sale price
- 6.25
- Shares outstanding
- 111,488,849
- Common shares registered
- 11,735,356
- Series b preferred shares issued
- 3,697,235
- Conversion series b shares registered
- 18,486,175
Price after filing
Close on the filing date to close N calendar days later (from $6.13). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.